A clinical study published yesterday in the Journal of Autism and Developmental Disorders found that cannabidiol (CBD) performed significantly better than placebo on a measure of motor skills in boys with severe autism, while also producing improvements in certain communication abilities compared with their pretreatment scores.
The research, conducted by scientists at the University of California San Diego, examined additional outcomes from a randomized, double-blind, placebo-controlled clinical trial involving boys with autism and substantial cognitive and behavioral challenges.
The new analysis included 30 boys who completed assessments of adaptive functioning. Participants were between 7 and 14 years old, with approximately 73% classified as nonverbal.
Researchers administered purified CBD in the form of Epidiolex, a pharmaceutical-grade cannabidiol medication, at doses reaching 20 milligrams per kilogram of body weight daily. Participants received CBD and placebo during separate eight-week treatment periods, with a four-week washout period between treatments.
Adaptive functioning was measured using the Vineland Adaptive Behavior Scales, Third Edition, a standardized assessment examining communication, daily living skills, socialization and motor abilities.
The clearest difference between the treatments appeared in motor skills. Researchers identified statistically significant differences favoring CBD over placebo in both standardized and raw motor scores.
However, the difference was primarily driven by worsening motor scores during placebo treatment rather than a statistically significant improvement from baseline during CBD treatment.
Researchers also identified improvements in communication abilities among participants receiving CBD.
Compared with their scores immediately before treatment, boys receiving CBD experienced statistically significant improvements in receptive communication, which involves understanding spoken language, and written communication. Improvements in expressive communication and personal daily living skills also approached statistical significance.
These communication gains were observed within the CBD treatment group, but the study did not establish statistically significant differences between CBD and placebo on the overall communication measures.
The findings build on results from the original clinical trial published in May 2025, which found that approximately two-thirds of participating boys demonstrated behavioral improvements during CBD treatment based on blinded clinical assessments. That earlier analysis also identified a substantial placebo effect, with no significant difference between treatments on the primary behavioral measures.
The newly published analysis focused specifically on adaptive functioning, including skills involved in communication, movement and everyday activities that were not detailed in the original report.
Researchers noted that the participants’ substantial developmental challenges made some improvements difficult to detect using conventional standardized scores. Examining raw scores allowed the researchers to identify changes that might otherwise have been missed.
Although the study did not demonstrate broad improvements across every measure of adaptive functioning, the findings provide additional evidence that purified CBD may benefit specific areas of functioning in some children with severe autism.
Researchers said larger clinical trials involving participants with different levels of autism severity are needed to determine whether the observed communication improvements translate into consistent benefits compared with placebo.










